Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II modified FOLFOXIRI plus bevacizumab in RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
jRCTs031180130Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Feb 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, irinotecan, oxaliplatin, fluorouracil and levoleucovorin in colorectal cancer (CRC), sponsored by Yakult Honsha. Primary endpoint: Response Rate. Started Feb 2015; status: completed.
02
Drugs
bevacizumabirinotecanoxaliplatinfluorouracillevoleucovorin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180130.